UBS has given Merck KGaA a "Buy" rating with a target price of 190 euros after the company's recent capital markets day.
Analyst Matthew Weston is confident in the stock's attractive valuation and supports the positive outlook for the pharmaceutical and specialty chemicals group.
This assessment follows a detailed review during the event, which highlighted the company's strategic direction and growth potential.
The report was published on October 22, 2024, and demonstrates UBS's ongoing commitment to monitoring key investment opportunities in the market.